T-DXd
Gastric Cancer
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan: The EN-hance study
Aoyama T, Ooki A, Oba K, et al.
Int J Clin Oncol. 2025 Jun;30(6):1162-1173. doi: 10.1007/s10147-025-02748-8.
Edoxaban
Cardiovascular - AF
Effectiveness and safety of edoxaban in the routine clinical care of atrial fibrillation patients in Brazil: Prospective 1-year follow-up study – EdoBRA
Precoma DB, da Silva RP, Passos LCS, et al.
Arq Bras Cardiol. 2025 Apr;122(4):e20240589. Portuguese, English. doi: 10.36660/abc.20240589.
HER3-DXd
Lung Cancer
Other/Multi
Exposure–response relationships in patients with non-small-cell lung cancer and other solid tumors treated with patritumab deruxtecan (HER3-DXd)
Li L, Lee M, Joshi R, et al.
Clin Pharmacol Ther. 2025 Apr. doi: 10.1002/cpt.3674
Valemetostat
Hematology
Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding
Tachibana M, Siebers N, Craveiro TV, et al.
Cancer Chemother Pharmacol. 2025 Apr;95(1):54. doi: 10.1007/s00280-025-04771-y.
Pexidartinib
Other/Multi
Patient-reported continued benefits of pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States
Dai D, Pan I, Freivogel K, Ye X, Tecson K, Tap W
Oncologist. 2025 Mar;30(3):oyaf028. doi: 10.1093/oncolo/oyaf028.
Valemetostat
Hematology
Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo
Sedohara A, Koibuchi T, Yamagishi M, et al.
Front Microbiol. 2025 Apr;16:1581330. doi: 10.3389/fmicb.2025.1581330.
Other/Multi
Breast Cancer
Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
Wróbel A, Vandenberghe M, Scott M, et al.
Diagn Pathol. 2025 Apr;20(1):35. doi: 10.1186/s13000-025-01624-3.
Other/Multi
Breast Cancer
Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: An observational cohort study
Lam C, Varghese D, Collins J, et al.
Oncologist. 2025 Apr;30(4):oyae280. doi: 10.1093/oncolo/oyae280.
Edoxaban
Cardiovascular - AF
Real-world evidence comparing oral anticoagulants for NVAF in Europe: A systematic review and network meta-analysis
Cichewicz A, Jawla S, Zuchinali P, et al.
Future Cardiology, 21(6), 371–390. https://doi.org/10.1080/14796678.2025.2484119
Other/Multi
Breast Cancer
Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: A US real-world cohort study
Modi S, Zhang S, Byng D, et al.
Breast Cancer Res Treat. 2025 Jun;211(2):351-362. doi: 10.1007/s10549-025-07649-y.
